Corporate Profile
Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR (Diazoxide Choline) Extended-Release tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase III clinical development program.
Latest Quarterly Earnings
Press Releases
Events
Sep 26, 2023 9:00 AM EDT
Sep 26, 2023 8:10 AM EDT
Apr 3, 2023 10:10 AM EDT